Author details

Full Name

Henry S Friedman

Affiliation

ORCID

Career Start Year

1970

Papers

535

H Index

104

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37004712	Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trial.		2023
37935104	Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma.	J Clin Oncol	2023
35001215	Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.	Supportive Care in Cancer	2022
34545753	Primary brain tumor patients admitted to a US intensive care unit: a descriptive analysis.	CNS Oncol	2021
35647401	Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience.	Adv Radiat Oncol	2021
34055377	Spiritual well-being and its association with health-related quality of life in primary brain tumor patients.	Neuro-Oncology Practice	2021
33732649	Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis.	Front Oncol	2021
33441554	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.	Nat Commun	2021
33441554	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy.	Nat Commun	2021
31440823	Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.	Supportive Care in Cancer	2020
32140975	Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series.	J Neurooncol	2020
32478924	Management of glioblastoma: State of the art and future directions.	Ca-A Cancer Journal for Clinicians	2020
31049419	Single-institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice.	Health Science Reports	2019
31686534	The role of chemotherapy in the treatment of central neurocytoma.	CNS Oncol	2019
31555453	Second primary cancers in long-term survivors of glioblastoma.	Neuro-Oncology Practice	2019
32642665	Performance of a nomogram for IDH-wild-type glioblastoma patient survival in an elderly cohort.	Neurooncol Adv	2019
30500933	MGMT: Immunohistochemical Detection in High-Grade Astrocytomas.	Journal of Neuropathology and Experimental Neurology	2019
31040154	MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.	Cancer Research	2019
31383442	Complementary and integrative health interventions and their association with health-related quality of life in the primary brain tumor population.		2019
29802247	The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.	Nat Commun	2018
30377587	Adjunctive perampanel for glioma-associated epilepsy.	Epilepsy and Behavior Case Reports	2018
29943666	Recurrent Glioblastoma Treated with Recombinant Poliovirus.	New England Journal of Medicine	2018
29097607	Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1-Induced Metabolic Liabilities.	Cancer Research	2018
29264836	Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.	Journal of Neuro-Oncology	2018
29093005	Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.	Cancer Research	2018
29666296	Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma.	Oncologist	2018
29564747	Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.	Journal of Neuro-Oncology	2018
29133513	Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.	Oncologist	2018
28096679	A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.	Therapeutics and Clinical Risk Management	2017
28669010	A cross sectional analysis from a single institution's experience of psychosocial distress and health-related quality of life in the primary brain tumor population.	Journal of Neuro-Oncology	2017
28411277	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.	Clinical Cancer Research	2017
29034361	THE CRITICAL ROLE OF NONHUMAN PRIMATES IN MEDICAL RESEARCH.	Pathog Immun	2017
28000417	A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group.	Pediatr Blood Cancer	2017
26984213	Vaccine Therapy, Oncolytic Viruses, and Gliomas.	Oncology	2016
27271867	Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ).	Support Care Cancer	2016
26025933	Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma.	Oncologist	2015
25563815	Prognostic marker analysis in pediatric intracranial ependymomas.	Journal of Neuro-Oncology	2015
25387895	Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.	Cancer Immunology Research	2015
25762141	Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.	Nature	2015
25949916	Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.	OncoImmunology	2015
26429914	Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells.	Journal of Biological Chemistry	2015
25054891	Bevacizumab therapy for glioblastoma: a passionate discussion.	CNS oncology	2014
24311632	Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.	Neuro Oncol	2014
24140581	The genetic landscape of anaplastic astrocytoma.	Oncotarget	2014
24722048	Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.	Oncotarget	2014
24939611	Oncolytic polio virotherapy of cancer.	Cancer	2014
24570103	Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.	Supportive Care in Cancer	2014
25115739	Impact of health-related quality of life and fatigue on survival of recurrent high-grade glioma patients.	J Neurooncol	2014
25115740	Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models.	Journal of Neuro-Oncology	2014
24880341	Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.	Nature Genetics	2014